Navigation Links
Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
Date:6/26/2008

LONDON, June 26 /PRNewswire/ -- Duke University Medical Center has licensed ALPHADAS(R) Logos Technologies electronic data capture (EDC) software to accelerate and streamline its early-phase clinical trials and to enable physicians to follow patients more closely.

Researchers at Duke, which will become the first academic medical center in the country to use the ALPHADAS system, believe the technology has the potential to be a more accurate, real-time system that may improve the safety of clinical trial participants and contribute to more timely development of new drugs.

The agreement was announced today at the 44th annual Drug Information Association meeting in Boston.

"We will be using this innovative system in our two clinical research units as well as in our new, 30-bed Phase I Duke Clinical Research Unit (DCRU)," said Robert M. Califf, MD, director of the Duke Translational Medicine Institute and vice chancellor for clinical research at the Duke University School of Medicine. "The Phase I trial program here will become the hub of our efforts in translational science. It's where we will do some of our most exciting work, which will focus on proof-of-concept studies evaluating the impact of new therapies on human systems biology."

Duke will pay for the project through support from the Clinical and Translational Science Award, a five-year, $53 million grant from the National Institutes of Health awarded to Duke in 2006. The grant is intended to transform how clinical and translational research is conducted, and enabling researchers to develop new treatments faster and deliver them to patients more efficiently and quickly.

Barry Mangum, PharmD, FCP, director of clinical pharmacology for the DCRU and associate clinical professor of clinical pharmacology at Duke University Medical Center, says the proprietary ALPHADAS software will run on the DCRU's computer system to capture, integrate and report on clinical data in real-time.

"In using this system, we will be able to capture and enter specific patient-safety data necessary for accurate adverse-event reporting, while also collecting other key data components that will aid us in designing a dose and dosing interval for that specific subject population," he said.

Logos Technologies has been providing early phase EDC and clinical site automation tools to the pharmaceutical industry for over 10 years, "We look forward to this opportunity to work with Duke, a leading and world class academic medical center," said Giles Wilson, BEng, co-founder of Logos Technologies. "The partnership will help us achieve our mission to reduce the development time of life-saving and life-enhancing drugs.

"We very much look forward to working with Logos Technologies to implement ALPHADAS at Duke" said Steve Woody, Associate CIO for Translational and Clinical Research for Duke Medicine. "We evaluated the market and believe ALPHADAS to be the best fit for our needs in developing a first-class proof-of-concept global effort."

http://www.logostechnologies.com

http://dukemednews.org


'/>"/>
SOURCE Logos Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... ... has named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of ... specializes in providing information destruction , recycling, and compliance services to ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
(Date:4/21/2017)... ... , ... The staff at Palm Beach Face is proud to announce that their practice founder, ... Set to take place on April 23rd, the London Marathon has a long tradition of ... part of team EMPOWER, raising money for the international charity, Smile Train. , ...
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its ... that the full potential of specialty and orphan brands can only be achieved when ... , “The Unifying Effect is at the heart of a true partnership between our ...
Breaking Medicine News(10 mins):